Bristol-Myers’ Fortunes to Finally Turn for the Better
Bristol-Myers Squibb has been a disappointing investment for over a quarter of a century now. At cents below $50 a share, the stock price...
All from BMY STOCK
Bristol-Myers’ Fortunes to Finally Turn for the Better
Bristol-Myers Squibb has been a disappointing investment for over a quarter of a century now. At cents below $50...
Undervalued Bristol Myers Stock Can Still Get Cheaper
It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for...
Undervalued Bristol Myers Stock Can Still Get Cheaper
It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical...
Bristol-Myers Stock Pattern Triggers a 37% Surge
Bristol-Myers Squibb and Celgene are expected to merge into a single company before the end of the year. The deal will create the fifth...
Bristol-Myers Stock Pattern Triggers a 37% Surge
Bristol-Myers Squibb and Celgene are expected to merge into a single company before the end of the year. The...
Bristol-Myers: Elliott Wave Setup can Double the Price
Bristol-Myers Squibb is in the process of acquiring Celgene in a $74 billion dollar cash-and-stock deal including debt. The deal faced opposition from hedge...
Bristol-Myers: Elliott Wave Setup can Double the Price
Bristol-Myers Squibb is in the process of acquiring Celgene in a $74 billion dollar cash-and-stock deal including debt. The...
